CN105025918A - 利尿钠肽、利尿肽或血管舒张肽用于治疗心血管适应症的方法 - Google Patents

利尿钠肽、利尿肽或血管舒张肽用于治疗心血管适应症的方法 Download PDF

Info

Publication number
CN105025918A
CN105025918A CN201480013163.1A CN201480013163A CN105025918A CN 105025918 A CN105025918 A CN 105025918A CN 201480013163 A CN201480013163 A CN 201480013163A CN 105025918 A CN105025918 A CN 105025918A
Authority
CN
China
Prior art keywords
hours
peptide
methods according
natriuretic peptide
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480013163.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍尔茨迈斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CARDIORENTIS Ltd
Original Assignee
CARDIORENTIS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CARDIORENTIS Ltd filed Critical CARDIORENTIS Ltd
Publication of CN105025918A publication Critical patent/CN105025918A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
CN201480013163.1A 2013-01-25 2014-01-24 利尿钠肽、利尿肽或血管舒张肽用于治疗心血管适应症的方法 Pending CN105025918A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25
US61/756,692 2013-01-25
PCT/IB2014/000253 WO2014115033A2 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Publications (1)

Publication Number Publication Date
CN105025918A true CN105025918A (zh) 2015-11-04

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013163.1A Pending CN105025918A (zh) 2013-01-25 2014-01-24 利尿钠肽、利尿肽或血管舒张肽用于治疗心血管适应症的方法

Country Status (19)

Country Link
US (2) US20140213520A1 (https=)
EP (1) EP2948165A2 (https=)
JP (1) JP2016505065A (https=)
KR (1) KR20150108903A (https=)
CN (1) CN105025918A (https=)
AP (1) AP2015008624A0 (https=)
AU (1) AU2014208851B2 (https=)
BR (1) BR112015017432A2 (https=)
CA (1) CA2898571A1 (https=)
DO (1) DOP2015000175A (https=)
EA (1) EA201500765A1 (https=)
IL (1) IL239909A0 (https=)
MX (1) MX2015009606A (https=)
NZ (1) NZ710246A (https=)
PH (1) PH12015501559A1 (https=)
SG (1) SG11201505492XA (https=)
TN (1) TN2015000315A1 (https=)
TW (1) TW201442722A (https=)
WO (1) WO2014115033A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105617360A (zh) * 2015-12-04 2016-06-01 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
CN110278941A (zh) * 2019-07-11 2019-09-27 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1995033769A1 (de) 1994-06-02 1995-12-14 Boehringer Mannheim Gmbh Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2425712C (en) * 2000-10-04 2017-06-06 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US8293711B2 (en) * 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
JP2011520917A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 慢性心不全の治療方法
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Ｓｉｒｓ患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
EP2480247B1 (en) * 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
WO2011113825A1 (en) * 2010-03-15 2011-09-22 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
BR112013003823A2 (pt) * 2010-08-20 2016-06-28 Cerulean Pharma Inc conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
US20060264376A1 (en) * 2005-04-07 2006-11-23 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105617360A (zh) * 2015-12-04 2016-06-01 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
WO2017092178A1 (zh) * 2015-12-04 2017-06-08 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测中的应用
CN110278941A (zh) * 2019-07-11 2019-09-27 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Also Published As

Publication number Publication date
TW201442722A (zh) 2014-11-16
AU2014208851B2 (en) 2016-12-22
IL239909A0 (en) 2015-08-31
WO2014115033A2 (en) 2014-07-31
BR112015017432A2 (pt) 2017-07-11
SG11201505492XA (en) 2015-08-28
AU2014208851A1 (en) 2015-08-06
PH12015501559A1 (en) 2015-09-21
KR20150108903A (ko) 2015-09-30
AP2015008624A0 (en) 2015-07-31
DOP2015000175A (es) 2015-11-15
WO2014115033A3 (en) 2015-02-26
EA201500765A1 (ru) 2015-12-30
US20140213520A1 (en) 2014-07-31
US20140213519A1 (en) 2014-07-31
CA2898571A1 (en) 2014-07-31
EP2948165A2 (en) 2015-12-02
NZ710246A (en) 2016-11-25
MX2015009606A (es) 2016-04-26
JP2016505065A (ja) 2016-02-18
TN2015000315A1 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
US9579363B2 (en) Method of lowering mortality
EP2510942B1 (en) Use of natriuretic peptide for treating heart failure
AU2009246112B2 (en) Method of treating chronic heart failure
CN105025918A (zh) 利尿钠肽、利尿肽或血管舒张肽用于治疗心血管适应症的方法
KR20170018829A (ko) Gdf-15를 감소시키기 위한 세렐락신의 용도
Bettencourt Brain natriuretic peptide (nesiritide) in the treatment of heart failure
TW202245792A (zh) 靜脈注射伊司他星用於治療急性心臟衰竭
WO2022029499A1 (en) Methods of treating refractory ascites
Predel et al. Atrial natriuretic peptide in patients with diabetes mellitus type I: effects on systemic and renal hemodynamics and renal excretory function
Liu et al. THE EFFECT OF SACUBITRIL/VALSARTAN COMBINED WITH METOPROLOL SUCCINATE SUSTAINED-RELEASE TABLET ON CARDIAC FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE.
US20230293640A1 (en) Compounds for the treatment of endotheliitis in context of virally caused diseases
WO2022029497A1 (en) Ularitide for use in methods of treating refractory ascites
HK1187550B (en) Treating dyspnea associated with acute heart failure with relaxin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151104

WD01 Invention patent application deemed withdrawn after publication